About this trial
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Eligibility criteria
Qualifiers
Local residents of Quzhou or living in Quzhou for over ten years.
age 40-50 and 60-70 years old, no major bad habits.
Gender unlimited.
in good health and has not undergone major surgery within half a year.
Disqualifiers
Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
Obesity (bmi more than 30).
Pregnant/lactating women.
Trial design
Treatments tested in this trial
- NMN
- placebo
Treatment groups
8
Treatment groupsSee each treatment group below.
Sponsors and collaborators
People's Hospital of Quzhou
Lead sponsor
Beijing Institute of Genomics, Chinese Academy of Sciences
Collaborator
Institute of Zoology, Chinese Academy of Sciences
Collaborator